Corbus names CCO, a new post, as it advances lead candidate

USA-based Corbus Pharmaceutical’s (Nasdaq: CRBP) has announced the appointment of  Craig Millian to the company as its first chief commercial officer ahead of the potential US Food and Drug Administration approval and commercial launch of its lead drug candidate lenabasum in 2021.

Mr Millian will develop and drive US and global marketing and commercialization strategies at Corbus, with an initial focus on lenabasum. He will serve on the senior management team and report to Yuval Cohen, chief executive officer.

Mr Millian brings 25 years of experience leading commercial organizations and a successful track record building pharmaceutical brands during all stages of development and commercialization. He most recently served as senior vice president and head of US Neurology and Immunology at EMD Serono, part of Germany’s Merck KGaA (MRK: DE), and prior to that served as VP of commercial at Vertex Pharmaceuticals. Prior to Vertex, he held commercial leadership roles at Pfizer and Sanofi.